<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266747</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5893</org_study_id>
    <nct_id>NCT00266747</nct_id>
  </id_info>
  <brief_title>An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder</brief_title>
  <acronym>AQUARIUS</acronym>
  <official_title>An Eight-Week,Dble-Blind,Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy, Safety and Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with
      Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 700 mg
      dose of SR58611A compared to placebo in patients with generalized anxiety disorder (GAD).The
      secondary objectives are to evaluate the efficacy of SR58611A on disability and quality of
      life in patients with GAD and to evaluate safety of SR58611A.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicenter, multicountry, randomized, parallel-group, double blind, placebo
      and paroxetine-controlled study consisting of three segments (A, B, and C). Segment A is a
      1-week, placebo, single-blind period and Segment B is an 8-week, double blind period. All
      randomized patients must complete a post-study visit 1 week after intake of the last dose of
      study medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The main secondary outcomes are the changes from baseline to Day 56 of treatment in the CGI Severity of Illness Score, percentage of patients with HAM-A treatment response and change from baseline in the HAM-A somatic and psychic anxiety factor scores.</measure>
  </secondary_outcome>
  <enrollment type="Actual">366</enrollment>
  <condition>Anxiety Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR58611A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out-patients, 18 to 65 years of age.

          -  Patients suffering from generalized anxiety disorder (GAD) as defined by Diagnostic
             and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR)
             criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI)
             plus GAD Module.

          -  With a total score on the 14-item Hamilton Anxiety Rating Scale (HAM-A) ³ 20.

          -  Having given voluntarily their written informed consent to participate in the study.

          -  Able to comply with the protocol and follow written and verbal instructions.

          -  For inclusion into Segment B of the study, patients must fulfill the following
             criteria:

          -  All Segment A inclusion criteria.

          -  Completion of a minimum of 3 and a maximum of 9 days of treatment in Segment A.

          -  Not &quot;placebo responders&quot; (i.e., improvement £ 20 % on HAM-A total score between V1 and
             V2)

        Exclusion Criteria:

          -  Patients with a diagnosis of Major Depressive Disorder as defined by DSM-IV-TR within
             6 months of study entry.

          -  Patients with a Montgomery-Asberg Depression Rating Scale (MADRS) total score of 18 or
             higher at screening or baseline visits.

          -  Patients having a moderate to high current risk for suicide.

          -  Patients with other current anxiety disorder assessed with the MINI: agoraphobia,
             social phobia, panic disorder, obsessive-compulsive disorder, post-traumatic stress
             disorder, acute stress disorder.

          -  Patients with a lifetime history according to the MINI of: bipolar disorders,
             psychotic disorders, antisocial personality disorder.

          -  Patients with severe or unstable concomitant medical conditions according to the
             Investigator's judgment.

          -  Females who are pregnant or lactating.

          -  Female patients of childbearing potential must use an effective method of birth
             control during the entire study period.

          -  Patients with positive test for any illicit drug included in the urine drug screen.

          -  Participation in a clinical trial of an experimental therapy within 3 months prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2005</study_first_submitted>
  <study_first_submitted_qc>December 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2005</study_first_posted>
  <last_update_submitted>March 10, 2009</last_update_submitted>
  <last_update_submitted_qc>March 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Anti-Anxiety Agents</keyword>
  <keyword>Controlled Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amibegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

